[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dciof6db06ad":3},{"user":4,"document":8,"mainDocument":27,"columnUrl":29,"subscription":30,"footer":42,"text":80},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},"dciof6db06ad","艾伯维(ABBV)最高25.4亿美元牵手德国Disco-Pharmaceuticals-加码下一代双特异性抗体抗癌疗法","\u002Fdoc\u002Fdciof6db06ad","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>\n\u003C\u002Fp>\u003Cp>\u003Cspan>美股投资网获悉，德国私营生物科技公司Disco Pharmaceuticals周四表示，艾伯维(ABBV)同意支付最高25.4亿美元，与Disco共同开发癌症疗法，这标志着该药企在下一代双特异性抗体疗法上的早期布局。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>双特异性抗体是一类可同时结合两个靶点的癌症药物，已吸引包括百时美施贵宝(BMY)、辉瑞(PFE)和默克(MRK)在内的大型药企日益浓厚的兴趣。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>今年1月，艾伯维向荣昌生物(RemeGen)支付6.5亿美元预付款，获得一款针对实体瘤的双特异性药物在中国以外地区的权益。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>作为此次合作的一部分，Disco将获得4000万美元预付款，以及最高25亿美元的里程碑付款，用于开发针对实体瘤的所谓“AND门控”(AND-gated)双特异性疗法。它还有资格获得基于全球净销售额的分层销售分成。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>这一方法的设计思路是，只有当两个靶点蛋白同时存在时才识别癌细胞，从而有可能减少对健康组织的损伤。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>Disco首席执行官马克·曼弗雷迪表示，其公司将负责研究与发现环节。艾伯维将拥有独家授权所选项目进行后续开发的权利。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>曼弗雷迪表示，“(艾伯维)带来了丰富的信息、丰富的靶点生物学经验，因此我们将向他们学习，并与他们合作来确定如何选择靶点。”\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>这笔交易尚处于非常早期的阶段。Disco未披露可能涵盖多少个项目、或何时能进入临床开发，而艾伯维的授权选择权仅在Disco完成指定研究后才生效。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>Disco一直在为小细胞肺癌和结直肠癌开发AND门控疗法，曼弗雷迪表示，公司将在明年下半年选定一个开发候选药物。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>近期其他双特异性抗体交易还包括百时美施贵宝与BioNTech(BNTX)最高111亿美元的合作，武田(Takeda)与中国信达生物(Innovent)数十亿美元的交易，以及优时比(UCB)以22亿美元收购Candid Therapeutics。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>最专业的美股资讯,推荐美股大数据 \u003Ca href=\"https:\u002F\u002FStockwe.com\u002F\">https:\u002F\u002FStockwe.com\u002F\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>如何识别美股市场异常波动？美国机构主力资金买卖情况，出货和吸筹，使用美股投资网VIP会员，2008年成立于美国硅谷，由前纽约证券交易所分析师Ken创立，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化模型，建立了一个股市数据库 \u003Ca href=\"https:\u002F\u002FStockWe.com\u002F\">https:\u002F\u002FStockWe.com\u002F\u003C\u002Fa> 每天处理千万级股票数据：捕捉期权大单，实时主力资金流向、机构持仓变化、川普突发新闻，精准交易信号第一时间发到您手机APP！\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003C\u002Fp>","https:\u002F\u002Fwww.tradesmax.com\u002Fimages\u002Fa_Stock\u002FA\u002FABBV\u002FABBV.jpg","2026-11-19T14:04:59","2026.11.19","2026\u002F11\u002F19",36090,[22],"ABBV","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":28,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},[22],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":31,"services":32,"recentDocuments":41},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" rel=\"noopener noreferrer\">\u003Cimg src=\"\u002Fimg\u002Fstockwewebfiles\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[33,37],{"productId":34,"serviceName":35,"priceText":36},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":38,"serviceName":39,"priceText":40},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":43,"images":71,"summaryHtml":76,"aboutTitle":77,"aboutHtml":78,"copyrightHtml":79},[44,47,50,53,56,59,62,65,68],{"label":45,"url":46},"深度报告","\u002Fcol\u002FdepthReport",{"label":48,"url":49},"VIP会员","\u002Fvip",{"label":51,"url":52},"期权推荐","\u002FOption",{"label":54,"url":55},"低价暴涨股","\u002FPenny",{"label":57,"url":58},"AI智能体","\u002FAiAgent",{"label":60,"url":61},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":63,"url":64},"美股课程","\u002Fcol\u002Fvideos",{"label":66,"url":67},"免责声明","\u002Fdisclaimer",{"label":69,"url":70},"联系我们","\u002FContactUs",[72,73,74,75],"\u002Fimages\u002Ffooter\u002Ffooter-1-wechat.gif?v=20260930c","\u002Fimages\u002Ffooter\u002Ffooter-2-telegram.png?v=20260930c","\u002Fimages\u002Ffooter\u002Ffooter-3-whatsapp.png?v=20260930c","\u002Fimages\u002Ffooter\u002Ffooter-4-line.png?v=20260930c","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 \u003Ca href=\"https:\u002F\u002Fstockwe.com\" rel=\"noopener\">StockWe.com\u003C\u002Fa> 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理海量股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，美股买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":81,"search":82,"searchPlaceholder":82,"hotContent":83,"draft":84,"noData":85,"searchNoData":86,"courseContent":87,"more":88,"buyNow":89,"subscribeNow":90,"encoding":91,"paidContent":92},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]